MedTrace Logo

Losartan and Emotion Processing

NCT03396523 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2018-06-06

No results posted yet for this study

Summary

The aim of the study is to investigate the effect of losartan (50mg, single dose) on the extinction of conditioned fear

Conditions

  • Healthy

Interventions

DRUG

Losartan

administration of losartan (50 mg) (oral)

DRUG

Placebo Oral Tablet

administration of placebo (oral)

Sponsors & Collaborators

  • University of Electronic Science and Technology of China

    lead OTHER

Principal Investigators

  • Benjamin Becker, PhD · University of Electronic Science and Technology of China

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-04
Primary Completion
2018-10-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03396523 on ClinicalTrials.gov